The Conversation (0)
August 26, 2024
Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to present its Annual Report.
Click here for the full ASX Release
This article includes content from Cleo Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
COV:AU
21 May 2024
Cleo Diagnostics
Revolutionising Ovarian Cancer Diagnosis Through Accurate and Early Detection
Revolutionising Ovarian Cancer Diagnosis Through Accurate and Early Detection Keep Reading...
17 March 2025
CLEO Delivers Commercial Development Milestone
Cleo Diagnostics (COV:AU) has announced CLEO Delivers Commercial Development MilestoneDownload the PDF here. Keep Reading...
27 February 2025
Appendix 4D and Half Yearly Accounts
Cleo Diagnostics (COV:AU) has announced Appendix 4D and Half Yearly AccountsDownload the PDF here. Keep Reading...
31 January 2025
Quarterly activities and cashflow report
Cleo Diagnostics (COV:AU) has announced Quarterly activities and cashflow reportDownload the PDF here. Keep Reading...
09 December 2024
CLEO Further Expands Ovarian Cancer Trial with Siles Health
Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles HealthDownload the PDF here. Keep Reading...
26 November 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialDownload the PDF here. Keep Reading...
05 January
Pathways to Commercialising Biotech Innovations
In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
25 February 2025
HeraMED Signs Strategic Collaboration Agreement with Garmin Health
HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
23 January 2025
Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®
Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
23 January 2025
CONNEQT App Launches in USA as Pulse Deliveries Commence
Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
16 January 2025
Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities
The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...
06 January 2025
Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025
Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00